[Therapeutic effectiveness of carminomycin (CRM) in combination with dibromodulcitol (DBD) compared with the combination vincristine, cyclophosphamide, methotrexate, 5-fluorouracil (VCMF) on some tumor systems (author's transl)].
The antineoplastic effectivity of VCMF was compared with the combined therapy CRM plus DBD in the mouse tumor systems L1210, 1142 A and Lewis lung carcinoma. Therapy of tumor-bearing mice was carried out by administering doses on the basis of LD 10 or with doses directly calculated from the clinical study CMEA 0102. In the most of all experiments VCMF was superior to the combination CRM plus DBD.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002360:Carubicin / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003630:Daunorubicin / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D008815:Mice, Inbred Strains; D008936:Mitolactol / Q000627:therapeutic use*; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014750:Vincristine; D003520:Cyclophosphamide; D002360:Carubicin; D008936:Mitolactol; D005472:Fluorouracil; D008727:Methotrexate; D003630:Daunorubicin
Therapeutische Effektivität von Carminomycin (CRM) in der Kombination mit Dibromodulcitol (DBD) im Vergleich zur Kombination Vincristin, Cyclophosphamid, Methotrexat, 5-Fluorouracil (VCMF) an verschiedenen Tumormodellen.